Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This is a combination study to evaluate sapacitabine administered in alternating cycles with
decitabine in previously untreated Acute Myeloid Leukemia (AML) or concomitantly with
venetoclax in previously treated AML or MDS